Brought to you by 
Generics company Vensun raises $22.5mm in Series C round
02 Dec 2016
Executive Summary
Vensun Pharmaceuticals Inc. (generic drugs) raised $22.5mm in its Series C financing round. The round was led by Perceptive Advisors, and included participation from new investor Deerfield Management, along with existing investors JW Asset Management, company management, and entities affiliated with Dr. Allen Chao, the co-founder of Watson Pharmaceuticals. Michael Altman of Perceptive was appointed to Vensun's Board.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Generics company Vensun raises $22.5mm in Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice